InflaRx shares surge 10.13% intraday as INF904 shows significant improvement in HS and CSU clinical trials.

InflaRx surged 10.13% intraday as INF904 demonstrated significant clinical improvements in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). In trials, 29 HS patients showed reduced abscesses/nodules and lower pain scores with sustained HiSCR response rates, while 30 CSU patients experienced a 13.7-point average reduction in UAS7 scores and a 15.4-point drop in severe cases.